Hypofractionated IMRT proved to be a feasible option for the treatment of localized prostate cancer since it has shown an acute toxicity profile similar to conventional fractionation, with GU toxicity ≥ grade 2 at 50% and GI toxicity ≥ grade 2 at 0% in the hypofractionation arm, while in the control arm GU toxicity ≥ grade 2 was 40% and GI toxicity ≥ grade 2 was 10%, with no statistical significance between them (p=0.689).